[Adobe Stock]
The explosive sales growth of GLP-1 drugs has analysts projecting that the antiobesity drugs could be a $44 billion market by 2030. Some observers are more upbeat, projecting that the sector could be worth more than $100 billion in the coming years. Pfizer CEO Albert Bourla projects that the market will reach $90 billion by 2031 with oral GLP-1 therapies contributing to the growth, Bloomberg quoted him as saying.But what if those figures are too low? While hurdles remain in terms of the drugs’ side effect profiles and payer backing, anti-obesity drugs could potentially find use for other conditions, concludes Truist director Dr. Joon Lee in a briefing note not specifically mentioning sales projections for the sector. In the long run, the drug class could find use not just for obesity but for conditions associated with elevated body weight. Examples run the gamut from neurodegenerative conditions s…